Phlegmasia coerulea dolens – Causes and Treatment
Phlegmasia coerulea dolens is a rare, life-threatening form of massive deep vein thrombosis causing severe limb swelling, intense pain, and a characteristic blue-purple skin discoloration.
Things worth knowing about "Phlegmasia coerulea dolens"
Phlegmasia coerulea dolens is a rare, life-threatening form of massive deep vein thrombosis causing severe limb swelling, intense pain, and a characteristic blue-purple skin discoloration.
What is Phlegmasia coerulea dolens?
Phlegmasia coerulea dolens (Latin: painful blue inflammation) is a severe, life-threatening complication of massive deep vein thrombosis (DVT). It occurs when nearly all of the deep veins of an extremity -- most commonly the leg -- become occluded by thrombus, causing critical venous outflow obstruction. This results in extreme swelling, intense pain, and a characteristic blue-purple (cyanotic) discoloration of the skin. Without rapid treatment, the condition can progress to tissue death (gangrene), limb loss, and in severe cases, death.
Causes and Risk Factors
The condition arises from an extensive thrombosis that blocks most of the deep venous system of a limb, nearly completely interrupting venous blood return. Common causes and risk factors include:
- Advanced malignancies (especially pancreatic, lung, and colorectal cancer)
- Prolonged immobility or bed rest
- Severe heart failure or circulatory shock
- Hypercoagulable states (e.g., antiphospholipid syndrome, Factor V Leiden mutation)
- Major surgery, particularly pelvic or hip procedures
- Pregnancy and the postpartum period
- Severe dehydration
- History of prior deep vein thrombosis
Symptoms
The clinical presentation of phlegmasia coerulea dolens is distinctive and rapidly progressive:
- Massive swelling of the entire affected extremity
- Severe, burning pain in the affected leg or arm
- Blue-purple skin discoloration (cyanosis) due to venous engorgement
- Skin tension and firmness
- Weakening or complete absence of arterial pulses in advanced stages
- Coldness and numbness of the affected limb
- In late stages: blistering, skin necrosis, and gangrene
- Systemic signs including hypotension, circulatory shock, and altered consciousness in severe cases
It is important to distinguish this condition from its milder precursor, phlegmasia alba dolens (painful white edema), in which venous obstruction is incomplete and the skin appears pale rather than cyanotic.
Diagnosis
Diagnosis is primarily clinical and confirmed by imaging studies:
- Duplex ultrasonography: The first-line imaging modality to confirm thrombosis and assess venous flow
- CT venography or MR venography: For precise mapping of thrombosis extent and planning of interventional procedures
- D-dimer: Markedly elevated in the blood, though non-specific
- Laboratory investigations: Complete blood count, coagulation parameters, renal and hepatic function, and workup for underlying conditions (e.g., tumor markers)
Treatment
Phlegmasia coerulea dolens is a medical emergency requiring immediate intensive care. The treatment goals are to prevent gangrene, pulmonary embolism, and death.
Conservative Treatment
- Immediate anticoagulation with unfractionated heparin (UFH) as a first-line measure to prevent further clot propagation
- Elevation of the affected extremity to promote venous drainage
- Intensive care monitoring and hemodynamic stabilization
- Adequate pain management and fluid resuscitation
Interventional and Surgical Treatment
- Catheter-directed thrombolysis (CDT): Dissolution of the thrombus through local delivery of thrombolytic agents (e.g., alteplase) via catheter -- the preferred approach in suitable patients
- Percutaneous mechanical thrombectomy: Mechanical removal of the thrombus using catheter-based devices
- Surgical thrombectomy: Operative thrombus removal, especially when interventional approaches are unavailable or contraindicated
- Fasciotomy: Surgical decompression when compartment syndrome is imminent
- Inferior vena cava filter placement: Considered in patients at high risk of pulmonary embolism who cannot receive thrombolytic therapy
Long-Term Management
Following acute treatment, long-term oral anticoagulation is indicated, with the duration determined by the underlying cause. In patients with active malignancy, low-molecular-weight heparin or direct oral anticoagulants (DOACs) are preferred. Identification and management of the underlying cause is essential.
Prognosis
The prognosis is serious: without prompt treatment, patients face a high risk of limb amputation, pulmonary embolism, and death. With timely and aggressive therapy, most limbs can be salvaged, but outcomes depend heavily on disease severity and the presence of comorbidities. Reported mortality rates range from 20 to 40% in the literature.
References
- Chinsakchai K. et al. - Trends in Management of Phlegmasia Cerulea Dolens. Vascular and Endovascular Surgery, 2011.
- Henke PK. - Contemporary management of acute limb ischemia: factors associated with amputation and in-hospital mortality. Annals of Vascular Surgery, 2007.
- Kearon C. et al. - Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 2016.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryMacronutrients
Portion control
Food craving
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Phlegmasia coerulea dolens-en